Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to develop an autoinjector for clinical and potential subsequent commercial supply of MoonLake’s Nanobody® M1095 (sonelokimab) by using SHL Medical's market-proven Molly® modular platform technology.
Lead Product(s): Sonelokimab,Adalimumab
Therapeutic Area: Immunology Product Name: M1095
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: MoonLake Immunotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 03, 2023